摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[3-(二甲基氨基)丙氧基]苯甲腈 | 146440-15-5

中文名称
4-[3-(二甲基氨基)丙氧基]苯甲腈
中文别名
——
英文名称
4-(3-(dimethylamino)propoxy)benzonitrile
英文别名
N-[3-(4-cyanophenoxy)-propyl]-dimethylamine;4-[3-(Dimethylamino)propoxy]benzonitrile
4-[3-(二甲基氨基)丙氧基]苯甲腈化学式
CAS
146440-15-5
化学式
C12H16N2O
mdl
——
分子量
204.272
InChiKey
XYCJVOUBTBJYTL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    15
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    36.3
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2926909090

SDS

SDS:e049ff65e8fe2516f9e6363a8f9048ba
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    摘要:
    本发明涉及一种抑制抗凋亡Bcl-2蛋白活性的化合物,包含该化合物的组合物以及用于治疗表达抗凋亡Bcl-2蛋白的疾病的方法。
    公开号:
    US20130267514A1
点击查看最新优质反应信息

文献信息

  • APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    申请人:Bruncko Milan
    公开号:US20100305122A1
    公开(公告)日:2010-12-02
    Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    揭示了抑制抗凋亡Bcl-2蛋白活性的化合物,含有这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-2蛋白的疾病的方法。
  • Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
    申请人:SOCIETE CIVILE BIOPROJET
    公开号:EP0978512A1
    公开(公告)日:2000-02-09
    Compounds of formula (I): and their use for preparing medicaments acting as antagonists at the H3-receptors of histamine.
    式(I)的化合物及其用于制备作为组胺H3受体拮抗剂的药物。
  • MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
    申请人:Birtalan Esther
    公开号:US20120108590A1
    公开(公告)日:2012-05-03
    A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.
    一种促凋亡的固态分散物包括本文所定义的化合物I公式的Bcl-2家族蛋白抑制剂,以基本非结晶形式分散在固态基质中,该基质包括(a)药学上可接受的水溶性聚合物载体和(b)药学上可接受的表面活性剂。制备这种固态分散物的过程包括将公式I的化合物、水溶性聚合物载体和表面活性剂暴露于高温下,以提供可挤出的半固体混合物;挤出半固体混合物;并冷却所得到的挤出物,以提供包含聚合物载体和表面活性剂的固态基质,并在其中分散化合物的基本非结晶形式。这种固态分散物适用于口服给予需要治疗由一个或多个抗凋亡Bcl-2家族蛋白过度表达所特征的疾病的患者,例如癌症或免疫或自身免疫性疾病。
  • Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
    申请人:——
    公开号:US20040220225A1
    公开(公告)日:2004-11-04
    Use of a compound of formula (A), wherein: 1 W is a residue which imparts antagonistic and/or agonistic activity at histamine H 3 -receptors when attached to an imidazole ring in 4(5) position; R 1 and R 2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H 3 -receptors of histamine.
    使用式(A)的化合物,其中:1W是一个残基,当附加在咪唑环的4(5)位时,赋予组合物在组胺H3受体上的拮抗和/或激动活性;R1和R2可以相同也可以不同,分别独立地表示较低的烷基或环烷基,或者与它们所连接的氮原子一起,表示饱和的含氮环(i)、非芳香性不饱和含氮环(ii)、吗啡环或N-取代哌嗪环,用于制备在组胺H3受体上作为拮抗剂和/或激动剂的药物。
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    申请人:Bruncko Milan
    公开号:US20110124628A1
    公开(公告)日:2011-05-26
    Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    本发明涉及一种抑制抗凋亡Bcl-2蛋白活性的化合物,含有该化合物的组合物以及治疗表达抗凋亡Bcl-2蛋白的疾病的方法。
查看更多